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Abstract
Group B Streptococcus (GBS), a commensal organism, can turn into a life-threatening
pathogen in neonates and elderly, or in adults with severe underlying diseases such as dia-
betes. We developed a vaccine targeting the GBS glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH), a glycolytic enzyme detected at the bacterial surface, which was proven to
be effective in a neonatal mouse model of infection. Since this bacterium has emerged as
an important pathogen in non-pregnant adults, here we investigated whether this vaccine
also confers protection in an adult susceptible and in a diabetic mouse model of infection.
For immunoprotection studies, sham or immunized adult mice were infected with GBS sero-
type Ia and V strains, the two most prevalent serotypes isolated in adults. Sham and vacci-
nated mice were also rendered diabetic and infected with a serotype V GBS strain. For
toxicological (pre-clinical) studies, adult mice were vaccinated three times, with three con-
centrations of recombinant GAPDH adjuvanted with Allydrogel, and the toxicity parameters
were evaluated twenty-four hours after the last immunization. For the stability tests, the vac-
cine formulations were maintained at 4°C for 6 and 12 months prior immunization. The
results showed that all tested doses of the vaccine, including the stability study formula-
tions, were immunogenic and that the vaccine was innocuous. The organs (brain, blood,
heart, and liver) of vaccinated susceptible or diabetic adult mice were significantly less colo-
nized compared to those of control mice. Altogether, these results demonstrate that the
GAPDH-based vaccine is safe and stable and protects susceptible and diabetic adult mice
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against GBS infections. It is therefore a promising candidate as a global vaccine to prevent
GBS-induced neonatal and adult diseases.
Introduction
Streptococcus agalactiae, or Group B Streptococcus (GBS), is the leading cause of life-threaten-
ing bacterial infections in newborns [1]. In the past three decades, this bacterium have emerged
as a major cause of invasive infections in non-pregnant adults, mainly in individuals with more
than 65 years old or with underlying medical conditions [2–5]. Diabetes mellitus appears as the
most common predisposition for GBS bacteremia in this group [2, 5]. The case fatality rates
are higher in adults than in neonates [2, 6]. Eighty percent of human GBS isolates are resistant
to tetracycline and it has been recently proposed that the widespread use of this antibiotic from
1948 was responsible for the selection of few tetracycline-resistant clones particularly adapted
to the human host, thereby causing the emergence of GBS diseases in neonates in the 60s [7].
GBS express a capsular polysaccharide (CPS) and ten serotypes have been described to date (Ia,
Ib, and II–IX). While GBS serotype III strains are strongly associated with neonatal meningitis,
serotype V isolates emerged in the United States as the most frequent serotype causing invasive
disease in nonpregnant adults, followed by serotypes Ia and III [5]. These three capsular sero-
types are also associated with the vast majority of invasive infections in several European
countries [8–10]. The only available treatment against GBS infections is based on the use of
antibiotics. The implementation of the intrapartum antibiotic prophylaxis (IAP) in colonized
pregnant women contributed to the decrease of the early-onset manifestations of GBS diseases
(infection occurring in the first week of life). However, the IAP treatment has contributed to
the emergence of antibiotic-resistant clones [6] with no effect on the late-onset neonatal disease
(infections occurring between the first week and the first month of life). The rate of adult GBS
disease has not declined until now and the use of antibiotics will likely cause increased resis-
tance as observed with neonatal GBS isolates. Therefore, the development of a vaccine, as an
alternative approach to the current use of antibiotics, will benefit neonates, pregnant and non-
pregnant adults [11].
GBS vaccines have been initially developed by coupling capsular polysaccharide (CPS) anti-
gens to immunogenic protein carriers but the existence of distinct epitope-specific capsular
serotypes has hampered the development of a global GBS vaccine [12]. To avoid the selection
of mutants that escape immune recognition, the ideal human GBS vaccine should be directed
against structurally conserved antigens that are essential for GBS virulence and/or growth, but
none of the hitherto described candidate antigens fulfills these requisites.
We showed in a mouse model of neonatal GBS infection that GBS glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) is a valuable vaccine candidate. Maternal vaccination with the
recombinant form of this protein was highly effective in protecting the offspring against a lethal
infection with GBS [13]. Importantly, the antibodies raised against the bacterial GAPDH did
not react with the human GAPDH [13]. However, before being used in clinical practice, a vac-
cine must pass several rigorous pre-clinical tests to evaluate its safety, effectiveness, or possible
side effects [14]. Therefore, in this study, we conducted a comprehensive series of experiments
to evaluate the stability, systemic toxicity, and local reactogenicity of the rGAPDH vaccine.
These experiments were designed to identify any potential systemic and organ-specific toxicity,
and to evaluate the stability of the vaccine formulation. Moreover, given the increased cases of
adult infections with this pathogen, we assessed the effectiveness of rGAPDH vaccine against
GBSGAPDH Is a Safe and Stable Vaccine
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the infection caused by GBS in adult susceptible mice using two GBS strains, A909 and 2603V/
R, belonging to serotypes Ia and V, respectively. Since diabetes is present in 20–40% of non-
pregnant adults infected with GBS [2, 4, 5], we also tested the efficacy of rGAPDH vaccine in
mice rendered diabetic. The obtained results showed that rGAPDH vaccine is highly immuno-
genic and stable for at least 12 months at 4°C, and no systemic or organ specific toxicity were
observed. The protective assays proved that the vaccine constituted by GAPDH is effective
against the infections caused by GBS in susceptible and diabetic adult mice. These results iden-
tify GBS GAPDH as a valuable global human vaccine to prevent neonatal and adult GBS
diseases.
Materials and Methods
Animals
Balb/cAnNCrl mice were purchased from Charles River (Italy). All the animals were kept in
the animal facilities of the Institute Abel Salazar during the time of the experiments. Mice were
6–8 weeks of age at the beginning of experiences. They were housed in Techniplast ventilated
polycarbonate cages under positive pressure with hardwood bedding and provided with Muce-
dola Diet and fresh tap water, ad libitum, throughout the study. All animals were housed in
environmentally controlled cages with 40 air changes per hour.
Ethics statement
This study was carried out in strict accordance with the recommendations of the European
Convention for the Protection of Vertebrate Animals used for Experimental and Other Scien-
tific Purposes (ETS 123) and Directive 2010/63/EU and Portuguese rules (DL 113/2013). The
animal experimental protocol was approved by the competent national authority Direção
Geral de Alimentação e Veterinária (DGAV) (Protocol Permit Number: 0420/000/000/2008).
All animal experiments were planned in order to minimize mice suffering.
Bacteria
GBS A909 (NEM2526) and 2603V/R (NEM2433) belong to capsular serotype Ia and V, respec-
tively. They were grown in Todd-Hewitt broth or agar (Difco Laboratories) at 37°C.
Purification of recombinant GAPDH
E. coli BL21 (DE3) strain (Novagen) and the pET28a plasmid (Novagen) were used for produc-
tion of the recombinant GAPDH (rGAPDH) protein from GBS NEM316 as described previ-
ously [15].
Formulations
rGAPDH vaccine for protection and safety studies were formulated prior to immunization
with 10 μg (V10 group), 20 μg (V20 group), or 40 μg (V40 group) of protein, a dose corre-
sponding to 0.5, 1 and 2 mg/kg of rGAPDH, respectively, in a 1:40 PBS-Alhydrogel suspension.
The sham-immunized control animals received 200 μL of PBS (Vehicle control without Alhy-
drogel) or a 1:40 PBS-Alhydrogel suspension (Vehicle control with Alhydrogel). The vaccine
used in stability studies was formulated immediately after rGAPDH purification with 20 μg of
rGAPDH in a final volume of 200 μL of a 1:40 PBS-Alhydrogel suspension (Aluminium
hydroxide Gel; Brenntag) and was maintained at 4°C for 0, 6, and 12 months (S0, S6 and S12
groups, respectively).
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Vaccine safety studies
A total of 30 female Balb/c mice, in groups of 6, were injected s.c. three times, with a three-
week intervening period, with 200 μL of V10, V20, or V40. The sham-immunized controls
received 200 μL of PBS or 1:40 PBS-Alhydrogel suspension.
Cage side observations were performed daily and included evaluation of mortality, morbid-
ity, general health, and signs of toxicity. Clinical observations were performed twice a week.
Body weight was determined twice a week. Reactogenicity of immunization site was scored for
edema, ulcer, and erythema using a scale from zero for no symptoms to four for severe symp-
toms. Reactogenicity scoring was performed on all the mice in each study group after each dos-
ing. One day after administration of the last dose (Day 43), all animals were fasted overnight
and euthanized for interim necropsy. Prior to necropsy, terminal blood was collected from all
mice under Rompum/Imalgene 1000 anesthesia. Plasma was used for clinical chemistry analy-
ses which included alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT),
albumin, amylase, lactate dehydrogenase (LDH), complement component 3 (C3), creatine
kinase (CK), creatine kinase MB (CK-MB), total protein, creatinine, total bilirubin, glucose and
Clara cell secretory protein 16 (CC16). Moreover, quantitative tests of 24-hour urine were also
carried out with metabolic cages, for the evaluation of the levels of creatinine, N-acetyl-beta-D-
glucosaminidase (NAG), and urea. All reagents were obtained from PZ Cormay S.A with
exception of NAG reagents that were obtained from Diazyme Europe GmbH.
Plasma biochemical parameters were measured in duplicate on an AutoAnalyser (PRES-
TIGE 24i, PZ Cormay S.A). Urinary urea, creatinine and total proteins were measured in dupli-
cate according to previously described methods [16, 17]. Plasmatic Clara cell 16 was quantified
with an Enzyme Linked Immunosorbent Assay kit (USBiological) used according to the manu-
facturer's instructions.
Animals were subjected to a full gross necropsy. External features suggesting any abnormal-
ity, especially evidence of lymph node enlargement was register. After opening the chest and
abdominal cavities, an in situ examination was done. Heart, lungs, liver, spleen, kidneys, gas-
trointestinal tract, pancreas, thymus and injection site were studied. The individual organs
(liver, spleen, kidney, lung and heart) were removed and re-examined for gross morphology
changes. After examination, they were weighed, adequately sliced and fixed in 4% (v/v) neutral
buffered paraformaldehyde by diffusion, for 24h, and subsequently dehydrated with graded
ethanol and included in paraffin blocks. Xylene was used in the transition between dehydration
and impregnation. Sections of 5 μmwere cut from paraffin blocks on a microtome (Leica
Microsystems, Model RM2125) and mounted on silane coated slides. After dewaxing with
xylene and rehydrated with graded alcohol, slides were stained with hematoxylin/eosin and
examined under a light microscope (Zeiss Axio ImagerA1) by a certified veterinary pathologist.
For every visual field, the histopathological evidences of tissue damage were analyzed as previ-
ously described [18] and a total histopathological score was calculated for each organ, allowing
the comparison among all groups.
Vaccine stability studies
A total of 20 female Balb/c mice, in groups of 4, were injected subcutaneously (s.c.), three
times, with a three-week intervening period, with 200 μL of S0, S6 and S12 preparations con-
taining 20 μg of rGAPDH in a 1:40 PBS-Alhydrogel suspension. The sham-immunized control
animals received 200 μL of PBS or a 1:40 PBS-Alhydrogel suspension. Cage side and clinical
observations as well as evaluation of the reactogenicity of immunization site were performed as
described above for safety vaccination studies.
GBSGAPDH Is a Safe and Stable Vaccine
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Immunoprotection studies
Balb/c mice were injected subcutaneously (s.c.), three times, with a 3-week intervening period
with 20 μg dose of rGAPDH in a 1:40 PBS-Alhydrogel suspension. The sham-immunized con-
trol animals received 200 μL of 1:40 PBS-Alhydrogel suspension. Mice were infected i.p. with
0.3 ml of PBS containing 3x106 CFU of GBS A909, or 3x107 CFU of GBS 2603V/R, and sacri-
ficed at indicated timepoints. Survival curves were determined over a 20-day experimental
period. Prior to necropsy, terminal blood was collected from all mice under Rompum/Imalgene
1000 anesthesia. Blood was collected and analyzed for GBS counts and the serum was used for
cytokine analysis. The analyzed organs were aseptically removed, homogenized in PBS and
serial dilutions of homogenized organs were plated on Todd-Hewitt agar to enumerate bacte-
rial CFU.
Diabetes mouse model
Balb/c mice were injected subcutaneously (s.c.), three times, with a 3-week intervening period
with 20 μg dose of rGAPDH in a 1:40 PBS-Alhydrogel suspension. The sham-immunized con-
trol animals received 200 μL of 1:40 PBS-Alhydrogel suspension. One week after the second
immunization, diabetes was induced by i.p. administration of a single dose of streptozotocin
(Sigma) at 200 mg/kg freshly dissolved in 0.05M citrate buffer, pH 4.5 [19]. Plasma glucose lev-
els were measured by OneTouch Verio blood glucose meter system (LifeScan, Johnson and
Johnson Company). Serum glucose levels of control animals ranged from 75–195 mg/dl. Mice
showing non-fasting serum glucose levels above 600 mg/dl at the time of the third immuniza-
tion STZ-injection were considered diabetic and used for the study. Mice were infected i.p.
with 0.3 ml of PBS containing 3x107 CFU of GBS 2603V/R one week after the last immuniza-
tion and sacrificed 18h post-infection. Prior to necropsy, terminal blood was collected from all
mice under Rompum/Imalgene 1000 anesthesia. Peritoneal lavage was performed with 5 mL of
ice-cold PBS. The analyzed organs were aseptically removed, homogenized in PBS and serial
dilutions of homogenized organs were plated on Todd-Hewitt agar to enumerate bacterial
CFU.
Quantification cytokines and CRP
TNF-α, IL-6, IL-1β and C-reactive protein (CRP) were quantified with an Enzyme Linked
Immunosorbent Assay kit (eBioscience) used according to the manufacturer's instruction.
Antibody titration
Total IgG and rGAPDH-specific IgG antibodies titers were assessed in the plasma of immu-
nized mice by Enzyme Linked Immunosorbent Assay. Briefly, serial dilutions of the serum of
immunized mice were added to the wells of a microtiter plate (NUNC) coated with rGAPDH
(5 μg/mL) for two hours at room temperature.
A conjugated goat anti-mouse IgG-HRP (H+ L, 1:1000, SouthernBiotech) antibody was
then added and the plate was incubated for two additional hours at room temperature. The o-
phenylenediamine substrate solution (Pierce) was added and, after addition of the stop solu-
tion, the color reaction was measured immediately by the absorption at 450 nm using a spec-
trophotometer (Thermo Multiskan Ex).
Statistical analysis
All statistical analyses were performed in GraphPad Prism version 5.0 for Windows (GraphPad
Software, San Diego, California). For safety studies, one-way ANOVA with post-hoc Dunnett's
GBSGAPDH Is a Safe and Stable Vaccine
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Multiple Comparison Test with 95% of confidence was used to analyze the differences between
all groups and Alhydrogel group. For stability studies, a one-way ANOVA with post-hoc
Tukey’s t-test with 95% of confidence was used to compare the different tested groups. For col-
onization and cytokine analysis, unpaired Student’s t-test was used to determine the differences
between GAPDH-immunized and sham-immunized groups. For survival curve analysis, Man-
tel-Cox test was performed. Considering the abnormal distribution of the histopathological
score data, differences among groups were tested using the nonparametric Kruskal-Wallis test
followed by Dunn's test. A P value< 0.05 was considered statistically significant.
Results
Safety studies evaluation
Mortality and clinical observations. All mice survived to the assigned end point and
appeared outwardly healthy after exposure to the vaccine, with no visible physical disability or
behavior alterations.
Reactogenicity. Small nodules (< 3 mm) were only observable after necropsy at the site of
each injection in mice of the groups V10, V20, V40 and Alhydrogel alone. The nodules were
too small to be noticed by touch during reactogenicity observations. This was considered as a
normal reaction resulting from the vehicle components. Signs of edema or erythema were not
observable in any animal during the time of experiment.
Body weight and body weight increase. No significant effects on body weight and body
weight increase were observed during the study among all test groups. Overall, most animals
gained weight throughout the study.
Anatomical pathology and histopathology. There were no significant changes in organ
weights (Table 1) and no gross morphological changes. Microscopic analysis was performed
on several sections from different locations in every organ with a magnification of 40x in order
to guarantee a global and precise organ overview. This examination took into account the
severity of tissue organization, the degree of cellular degeneration, the amount of interstitial
inflammatory cells, and the existence and extension of tissue necrotic areas. In all groups, none
of these histopathological traits was detected in the vital organs studied and the total histopa-
thology score calculated for each organ did not show significant differences among groups
(data not shown).
Immunogenicity
The efficacy of a vaccine is closely associated with the strength of the induced immune
response [14]. To confirm the immunogenicity of vaccine, titers of IgG specific for rGAPDH
were determined in the serum of the animals twenty-four hours after the last immunization.
All tested vaccine doses (V10, V20, and V40) induced the production of IgG antibodies
against rGAPDH (Fig 1). The titer values show a tendency to increase with the dose of rGAPD-
H-Alhydrogel injected, but the observed differences are not statistically significant. As
expected, rGAPDH-specific IgG antibodies were not detected in the serum of the controls
(Vehicle and Alhydrogel).
Plasma and urine chemistry
The serological and urine biochemical parameters were evaluated in all animals and found to
be in normal range after repeated exposure to the vaccine compounds (Table 2). The parame-
ters evaluated were: hepatotoxicity by quantifying the levels of alanine transaminase (ALT),
aspartate transaminase (AST), lactate dehydrogenase (LDH) and albumin [20]; cardiotoxicity
GBSGAPDH Is a Safe and Stable Vaccine
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by assessing the levels of creatine kinases (CK) and specifically its isoform creatine kinase-MB
(CK-MB) [21]; and nephrotoxicity by measuring the levels of urea, creatinine and N-acetyl-
beta-D-glucosaminidase [22]. Moreover, to evaluate pancreatic and lung toxicity, the amylase
and clara-cell 16 were analyzed, respectively [23, 24]. The systemic toxicity was also considered
by quantifying the serum levels of glucose and total proteins.
Inflammatory parameters
Acute-phase proteins were used as markers for acute inflammation induced after rGAPDH
immunization. These acute-phase proteins are produced by cells or tissues in response to
inflammatory stimulus. The degree of inflammation can be evaluated by measuring the serum
level of these proteins [25].
The levels of the pro-inflammatory cytokines IL-1β, TNF-α, and IL-6 in the serum of the
animals were below detection level in all groups and the levels of C-reactive protein were not
significantly different between groups (Table 2).
Stability studies evaluation
The shelf-life is an important feature for any vaccine or drug to be used in humans, especially
when intended for use in low-income countries where it is often difficult to provide appropriate
Table 1. Organ weight in mice with different vaccine doses.
Organ Vehicle control (w/out Alhydrogel) Vehicle control (w/ Alhydrogel) rGAPDH (with Alhydrogel)
V10 V20 V40
Heart 0.006 ± 0.001 0.006 ± 0.001 0.006 ± 0.001 0.006 ± 0.001 0.006 ± 0.001
Lungs 0.52 ± 0.04 0.50 ± 0.04 0.59 ± 0.11 0.58 ± 0.09 0.51 ± 0.05
Kidneys 2.02 ± 0.33 2.14 ± 0.29 2.11 ± 0.34 2.40 ± 0.39 2.19 ± 0.20
Liver 8.91 ± 1.41 9.11 ± 1.34 8.99 ± 1.31 7.84 ± 1.42 9.74 ± 0.92
Spleen 0.08 ± 0.01 0.07 ± 0.01 0.08 ± 0.01 0.08 ± 0.01 0.08 ± 0.01
Values are expressed as mean ± S.D; Number of animals per goup = 6; V10—10 μg s.c.; V20—20 μg s.c.: V40—40 μg s.c. One-way ANOVA with post-
hoc Dunnett's Multiple Comparison Test, p > 0.05.
doi:10.1371/journal.pone.0144196.t001
Fig 1. rGAPDH vaccine is immunogenic at all tested doses. rGAPDH-specific IgG titers of 6 female Balb/
c mice per group, immunized three times with a three week interval, 24h after the third immunization with 10
(V10), 20 (V20) or 40 (V40) μg of rGAPDHwith 1:40 Alhydrogel, alhygrogel alone, or PBS. The ELISA plates
were coated with rGAPDH and revealed with goat anti-mouse IgG—HRP. Titers are represented as minimal
serum dilution necessary for the lost absorbance signal.
doi:10.1371/journal.pone.0144196.g001
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storage conditions [26]. The vaccine formulations were maintained at 4°C for 6 (S6) and 12
(S12) months before immunization. An immunization protocol similar to that of the safety
studies was used and the potency of the formulations was evaluated by comparing the resulting
specific antibody titers with those obtained with a fresh prepared formulation (S0).
Antibody titers
The titers of IgG antibodies against rGAPDH induced by vaccines stored at 4°C for 6 and 12
months were similar to those induced by a freshly prepared vaccine (Fig 2). Moreover, as
expected, rGAPDH-specific IgG antibodies were not detected in the serum of the controls
(Vehicle and Alhydrogel) (Fig 2). The levels of total IgG were similar between all groups (vacci-
nated and controls, data not shown). The storage of the vaccine did not alter the potency or the
specificity of the response.
Safety assessment of S0, S6, and S12 formulations
Treatment with S6 and S12 formulations had no life-threatening effect. All mice survived to
the assigned end point and appeared healthy outwardly after exposure to the vaccine, with no
Table 2. Biochemistry of plasma and urine collected 24h after the last vaccine injection.
Vehicle control (w/out Alhydrogel) Vehicle control (w/ Aldhydrogel) rGAPDH (with Alhydrogel)
V10 V20 V40
Plasma Parameters
Albumin (g/L) 32.61 ± 2.21 29.19 ± 4.65 29.86 ± 1.19 31.89 ± 1.81 30.91 ± 2.22
Total proteins (g/L) 51.84 ± 3.41 48.04 ± 1.09 47.22 ± 1.96 48.98 ± 3.08 47.34 ± 2.24
Glucose (mg/dL) 85.7 ± 30.7 106.6 ± 29.9 90.5 ± 25.8 86.2 ± 10.8 87.0 ± 25.8
CK-MB (U/L) 227.9 ± 30.3 230.9 ± 38.8 236.0 ± 97.6 224.1 ± 67.9 196.2 ± 53.8
CK (U/L) 1111 ± 265 1192 ± 397 1754 ± 721 1460 ± 476 1175 ± 546
ALAT (U/L) 31.7 ± 2.9 35.1 ± 11.5 34.0 ± 2.9 29.4 ± 4.7 31.0 ± 3.5
ASAT (U/L) 99.0 ± 19.2 92.5 ± 20.7 111.1 ± 37.2 112.1 ± 33.4 90.2 ± 26.7
LDH (mg/dL) 743.6 ± 360.7 633.6 ± 234.7 625.6 ± 107.7 677.4 ± 65.6 623.9 ± 203.5
Amylase (U/L) 966.2 ± 262.2 870.5 ± 197.6 1000 ± 251.9 867.2 ± 167.9 806.8 ± 101.9
C3 (mg/mL) 11 ± 3 11 ± 3 14 ± 4 9 ± 3 14 ± 5
Urea (mg/dL) 46.3 ± 11.3 47.9 ± 10.3 53.2 ± 22.6 45.5 ± 5.8 45.3 ± 9.7
Creatinine (mg/dL) 0.35 ± 0.08 0.35 ± 0.05 0.28 ± 0.12 0.35 ± 0.05 0.30 ± 0.10
CC16 (ng/mL) 125.1 ± 43.1 154.9 ± 29.3 161.3 ± 37.9 121.2 ± 55.5 116.4 ± 25.6
Urine Parameters
Urea (mg/24h) 4.47 ± 3.40 5.18 ± 2.68 5.48 ± 3.68 4.46 ± 2.35 4.91 ± 2.41
Creatinine (mg/dL) 57 ± 24 65 ± 14 70 ± 18 67 ± 22 66 ± 25
NAG (U/L) 12.04 ± 2.63 11.71 ± 3.95 15.80 ± 1.95 14.57 ± 3.6 11.56 ± 3.5
Inﬂammatory Parameters
IL-1β (pg/mL) BDL BDL BDL BDL BDL
IL-6 (pg/mL) BDL BDL BDL BDL BDL
TNF-α (pg/mL) BDL BDL BDL BDL BDL
CRP (ng/mL) 2.30 ± 0,76 2.50 ± 0.81 2.30 ± 0.30 2.40 ± 0.31 2.23 ± 0.62
Values are expressed as mean ± S.D; Number of animals per group = 6; BDL—Below detection Level; CK—Creatine kinase; CK-MB—Creatine kinase
MB; ALAT—Alanine aminotransferase; ASAT—Aspartate aminotransferase; LDH—Lactate dehydrogenase; C3—Complement component 3; CC16—
Clara cell secretory protein 16; NAG—N-acetyl-beta-D-glucosaminidase; IL—Interleukine; TNF-α—Tumor necrosis factor α; CRP—C-reactive protein.
One-way ANOVA with post-hoc Dunnett's Multiple Comparison Test, p > 0.05.
doi:10.1371/journal.pone.0144196.t002
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visible physical disability or behavior alterations, and with no difference in body weight associ-
ated with the immunization. The treatment with the vaccines and adjuvant alone produced
small nodules only observable after necropsy at the site of injection. The levels of the pro-
inflammatory cytokines IL-1β, TNF-α, and IL-6 in the serum of the animals were below detec-
tion threshold in all groups. The levels of C-reactive protein were not significantly different
between groups (Data not shown).
rGAPDH vaccination protects susceptible and diabetic adult mice from
GBS infections
To assess the effectiveness of rGAPDH vaccine against GBS infections in adult mice, immu-
nized adult Balb/c mice were infected with A909 (serotype Ia) or 2603V/R (serotype V). As
shown in Figs 3 and 4, rGAPDH immunization confers protection to adult mice against GBS
infections caused by both serotypes. The survival of rGAPDH-vaccinated mice, either infected
with serotype Ia or V, were significantly increased compared with the respective sham-immu-
nized group (Figs 3 and 4). Indeed, none of the immunized mice succumbed to the infection
(100% survival) whereas ~40% and ~60% of sham-immunized mice infected with serotype Ia
and V, respectively, died within the first 48h (Figs 3A and 4A). To investigate whether the lon-
ger survival of rGAPDH-vaccinated mice was associated with an early control of GBS growth,
we next determined organ colonization at 6h and 18h post-infection. When infected with GBS
serotypes Ia or V, lower numbers of viable bacteria were found in blood, heart, liver, and brain
of the rGAPDH-immunized mice, as compared with the sham-immunized controls (Figs 3B
and 4B). Lower bacterial levels were also found in the lung of rGAPDH-immunized animals
infected with serotype Ia (Fig 3B). Since non-pregnant adult humans with diabetes are highly
susceptible to GBS infections, we also evaluated the efficacy o rGAPDH vaccine in mice ren-
dered diabetic by streptozotocin induction and infected with GBS 2603V/R, i.e. a strain belong-
ing to the emerging serotype causing invasive disease in non-pregnant adults. As shown in
Table 3, rGAPDH vaccination rendered the diabetic mice more resistant to GBS infection,
Fig 2. rGAPDH vaccine preserves its potency after prolonged storage at 4°C. rGAPDH-specific IgG
titers of 4 female Balb/c mice per group, immunized three times with a three week interval, 24 h after the third
immunization with PBS, Alhydrogel and 20 μg of rGAPDH in a 1:40 PBS/Alhydrogel suspension prepared
fresh (S0) or conserved at 4°C for 6 (S6) and 12 (S12) months. The ELISA plates were coated with rGAPDH
and revealed with goat anti-mouse IgG—HRP. Titers are represented as minimal serum dilution necessary
for the lost absorbance signal. One-way ANOVA with post-hoc Tukey’s t-test. ns—not significant.
doi:10.1371/journal.pone.0144196.g002
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compared with sham-vaccinated diabetic mice. Indeed, 18h post-infection, lower levels of GBS
CFUs were observed in blood, heart, liver, peritoneum, kidney, spleen and brain of the
rGAPDH-immunized compared with the sham-immunized controls (Table 3).
To characterize the pro-cytokines associated with protection in rGAPDH-immunized mice,
IL-6, TNF-α, and IL-1β were analyzed 3h post-infection in blood, liver and spleen of both
groups. As shown in Figs 3C and 4C, an increased production of the pro-inflammatory cyto-
kines, mainly IL-6 and IL-1β, were observed in vaccinated mice. Indeed, compared to the
sham-immunized controls, the rGAPDH-immunized mice infected with either GBS serotype
Ia or V, presented higher levels of IL-6 in sera, spleen, and liver, and of IL-1β in liver. Higher
levels of TNF-α were observed in the spleen of immunized mice infected with GBS serotype V
(Fig 4C).
Fig 3. rGAPDH vaccination improves survival and induces protection against serotype Ia GBS infection in an adult mousemodel. A) Kaplan–Meier
survival curves. The lethality was monitored for 20 days. The numbers in parentheses represent the number of animals that survived out of the total number
of infected animals. B) Blood, liver, lung, heart and brain colonization 6 and 18 hours post-infection (6 hours—Sham and GAPDH-immunized n = 7; 18 hours
—Sham n = 7, rGAPDH-immunized n = 6) and C) sera, liver and spleen cytokine production 3 hours post-infection (n = 6 for both groups). Balb/c mice were
immunized three times, with a three week interval, with 20 μg of rGAPDH in 1:40 Alhydrogel or treated with Alhydrogel alone and infected i.p. with 3x106 CFU
of A909 (serotype Ia). Unpaired Student’s t-test. *p < 0.05; **p < 0.01; *** p < 0.001.
doi:10.1371/journal.pone.0144196.g003
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Discussion
In the past few decades GBS infections have been responsible for a significantly high morbidity
and mortality rates amongst nonpregnant adults, particularly in elderly or individuals with
chronic underlying conditions, such as diabetes [2–5]. Currently, the invasive disease in adults
is increasing and represents about two-thirds of all cases of GBS infections, with a case fatality
ratio of about 10–20% [4]. The antibiotic use as prophylactic measure in pregnancy and as
treatment in adult against GBS infections raised several obvious concerns regarding the emer-
gence and dissemination of antibiotic-resistant clones [6, 7, 27]. Moreover, while the use of
IAP for prevention of GBS disease since 1996 was highly effective at preventing early-onset dis-
eases, it did not changed the rate of late onset diseases, as well as the rates of stillbirths and pre-
maturity caused by GBS infections [28]. Thus, vaccination is considered as a promising and
complementary alternative since it could be easily and broadly applicable and could protect
Fig 4. rGAPDH vaccination improves survival and induces protection against serotype V GBS infection in an adult mousemodel. A) Kaplan–Meier
survival curves. The lethality was monitored for 20 days. The numbers in parentheses represent the number of animals that survived out of the total number
of infected animals. B) Blood. liver. lung. heart and brain colonization 6 and 18 hours post-infection and (6 hours—Sham n = 8. GAPDH-immunized n = 7; 18
hours—Sham n = 9. rGAPDH-immunized n = 8) C) sera. liver and spleen cytokine production 3 hours post-infection (n = 6 for both groups). Balb/c mice were
immunized three times, with a three week interval, with 20 μg of rGAPDH in 1:40 Alhydrogel or treated with Alhydrogel alone and infected i.p. with 3x107 CFU
of 2603V/R (serotype V). Unpaired Student’s t-test. *p < 0.05; **p < 0.01; *** p < 0.001.
doi:10.1371/journal.pone.0144196.g004
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not only adults, but also newborns without the inherent limitations and problems associated
with antibiotic use [29].
Since low levels of maternal antibodies to capsular polysaccharide antigens correlate with
neonatal susceptibility, efforts were concentrated in the production of a vaccine based on the
GBS capsular polysaccharide [30, 31]. However, this strategy is not consistent with the fact that
the distribution of the ten GBS serotypes can vary in space and time [32, 33]. Moreover, capsu-
lar polysaccharide switching has been recently reported in GBS [34]. The possibility of a shift
in serotype prevalence supports the need for a universal GBS vaccine based on a different anti-
gen [35]. Accordingly, Grandi and colleagues developed a vaccine utilising a component of
each of the three pilus identified so far in GBS [36]. However, a change in the pili variant was
described to occur in the case of Neisseria gonorrhoeae, rendering a promising vaccine ineffec-
tive [37]. Based on this observation, one might predict that, following vaccination with pilus
antigen, the immune selective pressure will select GBS pilus variants to escape immunity.
We have identified GAPDH as a valuable universal GBS vaccine candidate [13, 15]. In a
mouse model of GBS infection, maternal vaccination with rGAPDH or passive immunization
with anti-rGAPDH IgG antibodies conferred neonatal protection [13]. Since GAPDH is ubiq-
uitously expressed in all type of cells, including mammalian cells, we demonstrated that the
antibodies produced against the GBS GAPDH do not react with its human counterpart [13].
Eukaryotic and prokaryotic GADPH sequences display only two 10-aminoacid long identical
segments and we consistently showed that antibodies produced against either native or dena-
tured GBS GAPDH do not recognize human GAPDH [13].
In the present work, the protective effect of this vaccine was extended to adult susceptible
mice. We showed that adult mice vaccinated with rGAPDH are protected against GBS infec-
tions caused by the two serotypes, Ia and V, mostly associated with the human invasive disease
[5]. The survival of rGAPDH-vaccinated adult mice is significantly increased compared with
sham-vaccinated animals. Mice vaccinated with rGAPDH presented decreased number of
bacterial counts in blood, brain, and heart, compared with sham-immunized animals. This
Table 3. Organ colonization of rGAPDH and Sham-immunized diabetic mice infected with GBS serotype V strain 2603V/R.
Diabetic mice
Organs Sham-immunized (log CFU/organ) rGAPDH-immunized (log CFU/organ) P-valuea
Blood 4.35 ± 0.732 0.902 ± 0.462 0.0010***
Liver 5.22 ± 0.550 3.06 ± 0.216 0.0017**
Spleen 4.76 ± 0.505 3.16 ± 0.460 0.0329*
Lung 4.60 ± 0.665 2.46 ± 0.501 0.0198*
Brain 2.61 ± 0.625 0.189 ± 0.189 0.0014**
Heart 4.43 ± 0.908 1.52 ± 0.511 0.0114*
Kidney 4.18 ± 0.754 1.92 ± 0.300 0.0107*
Peritoneum 5.69 ± 0.887 2.93 ± 0.621 0.0204*
Mice were killed 18h post-infection and the organs collected for bacterial counts. Values are expressed as mean ± S.E.M.; Number of animals Sham-
immunized = 8. rGAPDH-immunized = 9;
aStudent’s t Test.
*p<0.05;
**p<0.01.
***p<0.001
doi:10.1371/journal.pone.0144196.t003
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observation is particularly important since endocarditis and meningitis are the two clinical
presentations of GBS invasive infections with the worst prognosis in terms of morbidity and
mortality [38, 39]. The rising incidence rate of GBS infections in non-pregnant adults has been
associated with the aging of the population and with the increasing prevalence of individuals
with underlying comorbidities, like diabetes mellitus [4, 5]. Thus, to mimic the impact of diabe-
tes in the susceptibility to GBS infections, we determined the efficacy of the rGAPDH vaccine
in a mouse model of streptozotocin-induced diabetes. Our results show that vaccination with
rGAPDH protects adult diabetic mice against GBS serotype V infection.
GAPDH is an essential cytoplasmic enzyme involved in the glycolytic pathway which,
despite the lack of standard signal sequences, has been found at the surface of unrelated GBS
isolates [13]. This abundant enzyme is most likely released upon cell lysis to then bind to the
surface of living bacteria [40]. GAPDH possesses a critical metabolic function, being essential
for bacterial growth in blood, and plays an important role in GBS virulence. Alike GAPDH,
other metabolic and cytosolic proteins have been also detected at the surface of numerous
microorganisms where they exert a distinct function, being therefore called “moonlighting”
proteins [41]. In pathogens, extracellular “moonlighting” proteins are often involved in coloni-
zation and invasion of host tissues and we previously reported that cell surface bound GAPDH
confers to GBS the ability to bind plasminogen and fibrinogen [42, 43] and displays immuno-
modulatory properties that contributes evasion from the host immune system [13, 15]. The
potential of these “moonlighting” proteins as a vaccine target have also be experimentally
assayed [44–47] in other streptococci. For example, the α-enolase of Streptococcus sobrinus and
Streptococcus suis [46, 47], the fructose-bisphosphate aldolase of Streptococcus pneumoniae’
[45] and the arginine deiminase and the trigger factor of Streptococcus pyogenes [44] were char-
acterized as protective antigens.
To move a candidate vaccine from the laboratory to the clinic, preclinical tests including
safety studies in animals are mandatory [14, 48]. The evaluation of toxicological parameters of
repeated administration of rGAPDH-Alhydrogel formulations showed no effect on mortality,
clinical appearance, behavior, or body weight change. In the first months of life, newborns pro-
tection against infectious diseases is highly dependent on passive immunity mediated by moth-
er’s specific IgG antibodies that are transferred trough the placenta [49]. Therefore, a maternal
vaccine aimed at protecting the newborn should elicit high levels of IgG antibody [48]. Consis-
tently, our results showed that all tested doses of GAPDH were immunogenic and induced
high and similar levels of specific rGAPDH IgG antibodies. Gross and histopathological exami-
nations revealed no obvious abnormalities in organs and tissues of vaccinated mice. Moreover,
the biochemical characterization of serum samples confirmed the innocuity of the vaccine
deduced from the histological data. The serum levels of acute phase proteins or organ specific
markers were not altered by the immunization, which indicates that rGAPDH vaccination
does not induce acute inflammation or organ toxicity. Therefore, our study demonstrates the
safety and immunogenicity of the rGAPDH vaccine. The WHO guidelines for nonclinical and
clinical evaluation of vaccines stress a need for stability data to support clinical trial approval
[50] and we showed here that the rGAPDH vaccine conserves its potency and safety, without
significant alteration, at 4°C for at least 12 months.
This study predicts a potential application of rGAPDH vaccine in humans to prevent GBS-
induced adult and neonatal diseases.
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